Alterome Therapeutics schedules first Phase 1 clinical data presentation for pan-KRAS inhibitor ALTA3263
Alterome Therapeutics will reveal first ALTA3263 Phase 1 data in November, testing the safety and early activity of its oral pan-KRAS inhibitor.
Pharma & Biotech